Monthly Fund Fact Sheet
April 2023

Te Ahumairangi
GLOBAL EQUITY SPECIALISTS

About the Fund

The Te Ahumairangi Global Equity Fund is a portfolio of investments in 150-180 listed companies around the world. The fund invests primarily in companies that are based in developed economies, in North America, Asia, and Europe.

We aim to invest mainly in companies where we believe we have good visibility about how the company will generate sufficient cashflows to deliver good long-run returns to shareholders. We favour investing in lower-risk companies that produce stable profits, are not too sensitive to the economic cycle, and whose share prices are not excessively volatile or overly sensitive to investor sentiment. We believe this means that our fund is likely to withstand market downturns better than the average global equity fund.

Unit Price (NZD)	**1.1865** 28 April 2023
Monthly Return	**+3.80%** After fees, before tax. April 2023
Return to date	**+12.53%** per annum After fees, before taxes. Since fund inception, 5 November 2021
Fund Size	**$144.9 million*** * *Includes fund flows effective 28 April*
Fund Type	**Portfolio Investment Entity**
Minimum Investment	**$100,000 direct, or $250 through InvestNow.**
Investment Manager	**Te Ahumairangi Investment Management Ltd**
Issuer and Fund Manager	**FundRock NZ Ltd**
Supervisor	**Public Trust**
Custodian	**BNP Paribas**
Registry	**Apex Investment Administration (NZ) Ltd**
Management Fees	**0.60% per annum plus GST (approx 0.63% including GST)**
Performance Fees	**None**

Global Equities as an Investment

Over 95% of the fund will typically be invested in global equities. Although we aim to build a portfolio that is less sensitive to market conditions than the average global equity fund, investors should appreciate that our fund is nonetheless likely to fall in value if global equity markets decline. It could also fall in value if the New Zealand dollar rises. Global equities may not therefore be a suitable investment for people who expect that they may need to sell their investment portfolio within the next few years.

For long-term investors, it will often make sense to hold global equities as part of a diversified portfolio that also includes fixed interest investments and possibly other investments such as New Zealand equities. Global equities provide a level of diversification that is difficult to achieve from New Zealand equities alone.

A relatively high allocation to global equities will generally be more appropriate for investors who expect to continue saving money and contributing to their investment portfolio for the next few years. Higher allocations to global equities would also be more appropriate for investors who are psychologically prepared for the possibility of incurring investment losses in any given year.

Lower allocations to equities would generally be appropriate for investors who would find it psychologically difficult to deal with investment losses in any year or expect to be relying on their investment portfolio to fund their living expenses over the next few years.

Investors who are unsure about what place global equities should have in their investment portfolios should consult a financial advisor.

Risk Indicator:



For more information on the risks associated with this fund, please see the Product Disclosure Statement (PDS).

Please see the Important Notice and Disclaimer at the bottom of page 4.

Performance Update

Global Equity markets rose in April. Developed country equity markets (as represented by the MSCI World index) returned +1.65% (including gross dividends) in local currency terms. After adjusting for currency movements, the MSCI World index rose +3.12% (gross) in NZ dollar terms.

Indices of lower-risk equities outperformed the broader global equity market. The fund's benchmark index returned +3.38% in New Zealand dollar terms in April.

Share market returns were positive (in NZ dollar terms) from all sectors and all geographic regions during the month. Consumer Staples, Health Care, Energy, and Communication Services did slightly better than the rest of the market, while Information Technology & Materials lagged the rest of the market. European share markets produced better returns than other regions.

Benchmark Index

We compare the fund's performance to a composite benchmark index calculated by MSCI. The benchmark is a 50:50 combination of the MSCI World Index and the MSCI World Minimum Volatility (NZD) Index. The composition of the MSCI World Minimum Volatility (NZD) Index is calculated by MSCI to minimise volatility for NZ-dollar-based investors (subject to various constraints).

When benchmarking the fund's performance, we compare it to the gross return version of the benchmark, which makes no deduction for withholding taxes. This differs from the common practice of many other NZ-based funds, which compare their funds' pre-tax returns to the net return versions of their benchmark indices. This presents a lower hurdle for those funds' investment managers, as the net return indices assume high levels of withholding tax on dividend income.

Te Ahumairangi Investment Management considers the practice of these other funds to be misleading, as it does not provide investors with a like-for-like comparison for their funds' returns.

The fund returned +3.80% in April (after fees, but before taxes). This was an out-performance in comparison to the benchmark index, which returned +3.38%. Key factors which affected relative performance were:

- The sources of the Fund's relative performance were diverse during the month, with no individual fund holding either contributing or detracting more than 0.1% during the month. The individual biggest contributor was a relatively small holding in LG Chem preference shares, which rose 23.6% during the month.
- The relative performance of the Fund benefitted from the fact that it did not own any Tesla shares. Tesla's share price declined -19.8% during the month, dragging down the performance of the benchmark index that we use to compare the fund's performance by -0.11%.
- The Fund achieved better-than-benchmark returns in 8 out of 11 industrial sectors. Relative performance was strongest in the Energy, Industrials, Health care, and Information Technology sectors.
- The Fund outperformed the benchmark in all major countries except Canada.
- The Fund's allocation between countries and sectors also modestly contributed to relative performance during the month.
- The Fund's holdings of cash detracted -0.10% from the Fund's performance for the month, and currency hedges detracted -0.04%. Fees reduced the monthly return by -0.05%.

Since inception (5 November 2021), the fund has returned +12.53% per annum, outperforming its benchmark index by +6.97% per annum.

Please see the Important Notice and Disclaimer at the bottom of page 4.

Portfolio Composition

The table below shows the fund's top 10 equity investments at the end of April.

Company	Percentage of fund	*Company's weight in benchmark index*
Microsoft Corp	3.39%	*2.30%*
Verizon Communications	2.92%	*0.73%*
Apple	2.33%	*2.65%*
Alphabet (includes 2 classes of security)	2.01%	*1.17%*
KDDI Corp	1.51%	*0.29%*
Sumitomo Mitsui Financial Group	1.50%	*0.05%*
WW Grainger	1.21%	*0.03%*
Check Point Software Technologies	1.16%	*0.01%*
Roche Holding (includes 2 classes of security)	1.11%	*0.78%*
KB Financial Group	1.08%	*0.00%*

The pie chart below shows how the fund is allocated between different geographical regions:



Source: Investment Manager records, using MSCI definition of country of domicile where available, Bloomberg definition if not.

The pie chart below shows how the fund is allocated between different industrial sectors:



Source: Investment Manager records, using Bloomberg GICS data for sector classification.

For a copy of our product disclosure statement, visit our website teahumairangi.co.nz

Please see the Important Notice and Disclaimer at the bottom of Page 4.

Fund Returns

	April 2023	One year to April 2023	Since Inception (5 Nov 2021 to 28 April 2023) annualised return
Return after fees but before taxes	+3.80%	+12.85%	+12.53%
Benchmark Return*	+3.38%	+8.08%	+5.56%

* See page 2 for a description of the benchmark index.

Portfolio spotlight: Merck & Co

1.05% of the fund is invested in Merck & Co.

Merck & Co is one of the world's largest pharmaceutical companies, with annual sales of US$58 billion. It is US-based, but sells its products globally. Merck develops new drugs and treatments for a wide range of diseases, with a particular emphasis on oncology, vaccines, and animal health.



Merck's ground-breaking cancer treatment, Keytruda, is a biologic drug that works by supporting the body's own immune system to attack cancer cells more effectively. It has been approved for the treatment of 18 types of cancer, including lung cancer, melanoma, and bladder cancer. Keytruda is rapidly becoming the standard of care in the field of oncology. Keytruda may reach $24 billion in sales in 2023, which would make it the world's highest annual-grossing drug.

Merck also has a diversified business that includes animal health and vaccines which are less sensitive to patent expirations and help to mitigate the risks associated with drug development. Its animal health division is one of the largest in the world and has a broad range of products for both livestock and companion animals. Merck is also a leading producer of vaccines for a variety of diseases, including HPV, MMR, and pneumonia vaccines.

Important Notice and Disclaimer